Scinai Immunotherapeutics Ltd. Celebrates Dermatology Award for PC111 Research

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology, has announced a significant milestone in the development of PC111, a first-in-class anti-Fas Ligand monoclonal antibody. Dr. Roberta Lotti of Pincell Srl, a scientist whose research has been pivotal in advancing PC111, was awarded the prestigious 'Oscar of Italian Dermatology' by SIDeMaST. This accolade recognizes her groundbreaking study, 'Blocking soluble Fas Ligand ameliorates pemphigus,' which demonstrates PC111's efficacy in preventing blister formation by inhibiting keratinocyte apoptosis in pemphigus vulgaris, a severe autoimmune skin condition.

The recognition of Dr. Lotti's work by SIDeMaST not only highlights the scientific community's endorsement of PC111's potential but also marks a significant step forward in Scinai's efforts to develop non-immunosuppressive, disease-modifying treatments for autoimmune diseases. Scinai holds an option to acquire Pincell Srl, further solidifying its commitment to advancing PC111 as a lead asset in its pipeline. The company's focus on innovative solutions for diseases with large unmet medical needs is evident in its strategic approach to both in-house development and collaboration with early-stage biotech companies through its boutique CDMO services.

The implications of this development are far-reaching, offering hope to patients suffering from pemphigus vulgaris and potentially other autoimmune skin conditions. The award underscores the importance of continued research and investment in immunology and inflammation treatments, areas where Scinai Immunotherapeutics Ltd. is making notable contributions. For more information on Scinai's innovative pipeline and services, visit https://www.Scinai.com.